Physicochemical Properties
| Molecular Formula | C18H20N2O4S |
| Molecular Weight | 360.42 |
| Exact Mass | 360.114 |
| Elemental Analysis | C, 59.98; H, 5.59; N, 7.77; O, 17.76; S, 8.89 |
| CAS # | 1646499-97-9 |
| PubChem CID | 71598556 |
| Appearance | White to off-white solid powder |
| Density | 1.4±0.1 g/cm3 |
| Index of Refraction | 1.631 |
| LogP | 3.27 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 25 |
| Complexity | 556 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S(C1CC1)(NC1=CC=CC=C1C(NC1C=CC=CC=1OCC)=O)(=O)=O |
| InChi Key | RCSLEKLNDJJJLF-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C18H20N2O4S/c1-2-24-17-10-6-5-9-16(17)19-18(21)14-7-3-4-8-15(14)20-25(22,23)13-11-12-13/h3-10,13,20H,2,11-12H2,1H3,(H,19,21) |
| Chemical Name | 2-(cyclopropylsulfonylamino)-N-(2-ethoxyphenyl)benzamide |
| Synonyms | ML 382; ML-382; ML382 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | BAM8-22 suppresses ICa with an IC50 of 0.66 ± 0.05 μM when ML382 is not present. The BAM8-22 IC50 dropped to 0.43 ± 0.02 μM, 0.25 ± 0.02 μM, 0.06 ± 0.01 μM, and 0.08 ± 0.01 μM in the presence of 0.1 μM, 1 μM, 10 μM, and 30 μM ML382, respectively. Therefore, ML382 dose-dependently boosted the potency of BAM8-22, further revealing that ML382 is a positive allosteric modulator of MRGPRX1 [1]. Lower IC50 generally indicates higher potency. |
| ln Vivo | In MrgprX1 mouse DRG neurons, ML382 (5 μM) markedly enhanced the suppression of ICa induced by low concentrations of BAM8-22 (0.5 μM). In MrgprX1 mice, ML382 increases BAM8-22 inhibition of spinal synaptic transmission. ML382 (25 μM, 125 μM, and 250 μM; 5 μL; i.th.;) attenuates heat hypersensitivity in MrgprX1 mice in a dose-dependent manner. When compared to pretreatment values, ML382 (lumbar puncture injection; 25 μM, 5 μL) led to a significantly longer posttreatment duration in the ML382-paired chamber. In MrgprX1 mice, ML382 reduces chronic pain brought on by nerve damage [1]. |
| References |
[1]. Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain. Proc Natl Acad Sci U S A. 2017;114(10):E1996-E2005. [2]. Discovery and characterization of 2-(cyclopropanesulfonamido)-N-(2-ethoxyphenyl)benzamide, ML382: a potent and selective positive allosteric modulator of MrgX1. ChemMedChem. 2015;10(1):57-61. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~277.45 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7745 mL | 13.8727 mL | 27.7454 mL | |
| 5 mM | 0.5549 mL | 2.7745 mL | 5.5491 mL | |
| 10 mM | 0.2775 mL | 1.3873 mL | 2.7745 mL |